It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The checklist has been distributed to major hospitals and even little ones, including an urgent center in Leesburg, Va.
“Every hospital should ensure that it can detect a patient with Ebola, protect healthcare workers so they can safely care for the patient, and respond in a coordinated fashion,” warns the CDC.
Monsanto, or Monsatan as many call them, has partnered with the Department of Defense to use a proxy third party company to develop a vaccine against Ebola. The seed money began at $1.5 million. The value of the deal could grow to an estimated $86 million dollars. The company’s name is Tekmira Pharmaceuticals Corporation (TKMR) (TKM.TO), a leading developer of RNA interference (RNAi) therapeutics. “TKM-Ebola, an anti-Ebola virus RNAi therapeutic, is being developed under a $140 million contract with the U.S. Department of Defense’s Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office